ELEV News and Press, Elevation Oncology Inc. From 04/22/24

2024-04-22 11:00:17 ET Summary Elevation Oncology, Inc. has had a successful year, transitioning from the shelving of their seribantumab program to focusing on antibody-drug conjugates. Their flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promis...

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 PR Newswire -- On-track to nominate development candidate in 2024 -- BOSTON , April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an ...

2024-03-29 05:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-20 13:46:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s note: “How the Medical Industry Could Produce the Biggest AI Stock Winners” was previously published in March 2024. It has since been updated to include the most...

2024-03-06 11:25:10 ET Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors, computer processing hardware and the computer peripherals industries. Additionally, the biotech sector is +13.6% in 2024, outdoing all of the major market aver...

2024-03-06 10:00:14 ET More on Elevation Oncology Elevation Oncology: Rising On News, But Not The Time To Buy Elevation Oncology says its cash and cash equivalents enough to fund operations into 2H25 Seeking Alpha’s Quant Rating on Elevation Oncology H...

Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements PR Newswire --Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan ; on track to provide update in mid-2024 and ...

Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024 PR Newswire -- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing ca...

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors PR Newswire BOSTON , March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company f...

Elevation Oncology to Participate in Upcoming Investor Conferences PR Newswire BOSTON , Feb. 28, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...